Skip to main content

Advertisement

Table 5 Burden of Pseudomonas aeruginosa pneumonia stratified for multidrug-resistance

From: Measuring the in-hospital costs of Pseudomonas aeruginosa pneumonia: methodology and results from a German teaching hospital

 Hospital-acquired cases (HAP)Community-acquired cases (CAP) where the infection was not the main diagnosisCommunity-acquired cases (CAP) where the infection was the main diagnosis
Non-MDR-HAP (N = 126)MDR-HAP (N = 15)Non-MDR-CAP (N = 48)MDR-CAP (N = 15)Non-MDR- CAP (N = 27)MDR –CAP (N = 5)
Additional costs (in €)19,448.3***12,875.34051.7***27,251.06***6121.2***12,981.7
[12,472.7, 26,423.9][− 3890.0, 29,640.6][1971.6, 6131.7][7732.4, 46,769.6][2657.6, 9584.8][−25,078.8, 51,042.2]
Additional reimbursement (in €)17,729.8***4728.62647.5***18,070.3***5077.4***7676.6
[9943.0, 25,516.7][− 7346.2, 16,803.5][1196.5, 4098.6][12,582.8, 23,557.7][1979.8, 8175.0][−30,929.8, 46,283.1]
Additional length of stay (in days)9.524***6.693**5.102***15.483***9***25
[6.494, 12.554][1.532, 11.854][2.498, 7.705][10.490, 20.477][5.302, 12.697][−10.087, 60.087]
N55526232
  1. 95% confidence intervals in brackets, results of median regression
  2. * p < 0.1, ** p < 0.05, *** p < 0.01
  3. Results of multivariate quantile regressions including a case-control variable as well as CCI, sex, age, and age2 as fixed effects (HAP and CAP) and MDR-status as effect modifier. For HD-CAP cases univariate quantile regression was used